



BIOSIGN SIGNS COLLABORATION AGREEMENT WITH IBM

Companies to collaborate in delivering personal health monitoring services

TORONTO, ONTARIO, Tuesday, April 8, 2008 -- Biosign Technologies Inc. (CNQ: BIOS) today announced the signing of a collaboration agreement with IBM. Under the agreement, Biosign and IBM have formalized and agreed to accelerate an existing collaboration in commercializing advanced health monitoring services powered by Biosign's UFIT® system. The system leverages IBM's service oriented architecture (SOA) to allow customers to meet the strong demand for high-performance care in the patient-centric, personal health care and clinical research markets.

According to the Centers for Disease Control and Prevention, the medical care costs of people with chronic diseases account for more than 75% of the United States \$2 trillion plus medical care costs. The agreement between Biosign and IBM consolidates and coordinates the two companies' efforts to address the burgeoning epidemic in chronic disease including hypertension (high blood pressure), heart disease and diabetes.

"IBM has made a commitment to improve the lives of people where they live and work," said Sal P. Causi, IBM's Business Development Executive. "Today's healthcare challenges demand innovative, cost effective solutions that will ensure improved access to care and quality of care. We were seeking a robust global health monitoring technology with an intelligent alerting system for patients that would scale with WebSphere and other IBM deployments and Biosign's solution was a perfect fit."

Specifically, IBM will continue to offer Biosign's UFIT® health monitoring technology to its customers and IBM Business Partners. UFIT® is especially well suited for use with IBM's healthcare business offerings, including Acure and other health portals, WebSphere, Personal Care Connect and the "Smart Home" solution.

"IBM's global brand and focus on health care solutions aligns with Biosign's strategic goals. This agreement demonstrates our strong relationship and validates our complementary technologies," said Richard Potts, Chairman and Chief Executive Officer of Biosign. "IBM's expertise in IT infrastructure and telecommunications support, combined with access to regional partners, is unsurpassed in delivering national and global health care solutions. We are delighted to be working with IBM and its customers, and we're proud to be part of IBM's global health monitoring strategy," added Potts, noting that IBM has already made several significant connections. "Our vision and the urgent need to transform healthcare are all in harmony with the new IBM tagline: *Stop Talking – Start Doing.*"



By providing instant access to vital information in a standardized format, the companies are building an on-ramp to personal health monitoring. Such monitoring helps improve the quality of care through better data acquisition and improved patient-physician relationship. The companies expect this agreement to accelerate the path to commercializing solutions that enable prompt access to safe and efficient health care services.

About IBM

For more information about IBM healthcare, visit www-03.ibm.com/industries/healthcare/index.jsp
For more information about IBM WebSphere is available at: www.ibm.com/websphere/portal

About Biosign

Biosign develops technologies, products and initiatives to address critical problems in global health care. The company is committed to becoming the "world's health monitor" with a robust, integrated and portable system that provides valuable information for all parties concerned---patients, physicians, pharmacists, payors and pharmaceutical companies---and a wide range of potential revenue-generating services. Biosign's breakthrough technology and continued innovation serve the company's mission to make health care safe, simple, and sensible.

For more information about Biosign, visit www.biosign.com

Contact:

Biosign

Richard Potts
Chairman & CEO

Phone: (416) 218-9800 ext. 234
Email: richardp@biosign.com

Media inquiries
PRceptive Media Relations
Kathryn Schwab,
Phone: (613) 858-4407
Email: kschwab@prceptive.com

Forward-Looking Statements

This press release contains forward looking statements. Forward looking statements are not based on historical facts, but rather on current expectations, Company assumptions and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Company assumptions and risk factors are listed from time to time in Biosign's reports, public disclosure documents including Management's Discussion and Analysis, Management Information Circular, and in other filings with stock exchanges and securities regulatory authorities in Canada.

You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. While Biosign may elect to, Biosign is under no obligation and does not undertake to update this information at any particular time. This press release was prepared by management from information available to the date of this release.